Medicamen Biotech Ltd (MEDICAMEQ) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Medicamen Biotech Ltd on NSE and BSE, with an AI summary of each filing.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shivalik Rasayan Ltd & Growel Remedies Ltd
Acquisition/ Disposal of Shares · 26 Oct 2026, 9:44 pm
Shivalik Rasayan Increases Stake in Medicamen Biotech to 42.57% Shivalik Rasayan Limited, part of the promoter group of Medicamen Biotech Limited, acquired 5,00,000 equity shares (3.56% stake) via warrant conversion on a preferential basis on 23rd Oct'26. Following this allotment, Shivalik Rasayan's shareholding in Medicamen Biotech increased from 54,87,095 shares (40.46%) to 59,87,095 shares (42.57%). Consequently, Medicamen Biotech's total paid-up equity capital expanded from Rs 13.56 cr (1,35,62,815 equity shares) to Rs 14.06 cr (1,40,62,815 equity shares) of face value Rs 10 each.
Outcome of the meeting of Preferential Issue Commitee of the Board of Directors of Medicamen Biotech Limited to consider and approve the allotmentb of 5,00,000 Equity Shares pursuant to ....
Others (Uncategorized) · 23 Oct 2026, 5:31 pm
Medicamen Biotech Approves Equity Allotment via Warrant Conversion Medicamen Biotech Limited's Preferential Issue Committee approved the allotment of 5,00,000 equity shares upon conversion of equivalent fully convertible warrants on 23rd Oct'26. The shares were allotted to promoter group entity Shivalik Rasayan Limited at an issue price of Rs. 530 per share for cash, aggregating to Rs. 26.50 crore. Post-allotment, the company's paid-up equity share capital expanded to Rs. 14.06 crore, comprising 1,40,62,815 equity shares of face value Rs. 10 each.
Trading Plan under SEBI (PIT) Regulations 2015 - Mr Sanjay Bansal
Others (Uncategorized) · 30 Sept 2026, 10:30 pm
Medicamen Biotech Director Sanjay Bansal Sells Equity Stake Worth Rs 1.05 Crore Medicamen Biotech Limited director Sanjay Bansal executed an on-market sale of 32,813 equity shares between 28th Sep'26 and 30th Sep'26 for a total value of Rs 1,05,42,440. Prior to the transaction, Bansal held 1,02,813 shares (0.76% stake), which reduced to 70,000 shares (0.51% stake) post-disposal. The company submitted the required Form C regulatory disclosure under Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, following intimation on 30th Sep'26. No derivative transactions were reported.
Voting Results of 33rd Annual General Meeting - September 26, 2026
Annual General Meeting · 28 Sept 2026, 8:29 pm
Outcome of 33rd Annaul general Meeting held on Saturday, September 26, 2026 at 12.00 Noon.
Annual General Meeting · 26 Sept 2026, 9:01 pm
Medicamen Biotech Concludes 33rd AGM and Key Resolution Voting Medicamen Biotech Limited held its 33rd Annual General Meeting on 26th Sep'26 via video conferencing. Key resolutions tabled for shareholder approval included adoption of audited standalone and consolidated FY26 financial statements, dividend declaration on equity shares, re-appointment of retiring directors, and ratification of cost auditors' remuneration. Crucially, ordinary resolutions were presented to approve material related-party transactions with holding firm Shivalik Rasayan Limited and subsidiary Medicamen Life Sciences Private Limited. Remote e-voting concluded on 25th Sep'26, with final scrutinizer results to be disclosed post-meeting.
Reg 34 (1) Annual Report
Others (Uncategorized) · 04 Sept 2026, 12:08 am
Business Responsibilty and Sustainability Report - 2025-26
Others (Uncategorized) · 03 Sept 2026, 10:49 pm
Medicamen Biotech FY26 BRSR Highlights Strong Export Reliance and Environmental Compliance Medicamen Biotech reported a FY26 turnover of ₹178.84 crore and PAT of ₹9.41 crore. The pharmaceutical manufacturer generates 80% of sales from exports across 35 countries via three domestic facilities. Operations maintained zero safety incidents, zero product recalls, and zero liquid discharge. The company invested 22% of capital in R&D and increased MSME sourcing to 23%. CSR spending reached ₹25.20 lakh, with the unspent ₹6.13 lakh transferred to Schedule VII funds. A nominal ₹7,080 NSE penalty for delayed shareholding pattern filings was fully paid and regularized.
Submission of Integrated Annual Report for FY 2025-26
Annual General Meeting · 03 Sept 2026, 10:45 pm
Notice of 33rd AGM scheduled to be held on Saturday, September 26, 2026 through video conferencing/other audio visual means ("VC/OAVM")
Annual General Meeting · 03 Sept 2026, 10:43 pm
The Company has fixed Saturday, September 19, 2026 as the record date for determining the entitlement of members to receive the dividend, if declared at the ensuing AGM.
Dividend · 18 Aug 2026, 6:56 pm
Corporate Action- Fixes Record Date as September 19, 2026 for the purpose of declaration of final dividend for FY 2025-26.
Dividend · 17 Aug 2026, 9:15 pm
Medicamen Biotech Q1'27 Results: Profit Rises 15% YoY, Dividend Announced Medicamen Biotech reported a 15.2% YoY rise in consolidated net profit to ₹184.60 lakh for Q1'27 ended 30-Jun-26. Revenue from operations grew 11.3% YoY to ₹4,789.69 lakh. Standalone net profit increased 54.4% YoY to ₹252.69 lakh. The board approved a final dividend of ₹1/share (10%) for FY26, setting 19-Sep-26 as the record date. The company also noted fines from BSE and NSE totaling ₹1,10,920 each for non-compliance with LODR regulations, which were paid on 02-Jun-26.
Financial Results for the quarter ended on June 30, 2026.
Financial Result · 14 Aug 2026, 9:02 pm
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 14 Aug 2026, 5:30 am
Medicamen Biotech Board Meeting Scheduled for Q1FY27 Results Medicamen Biotech Ltd. has scheduled a Board of Directors meeting on Aug 14, '26, to consider and approve its unaudited standalone and consolidated financial results for the quarter ended Jun 30, '26. The agenda also includes approving the draft Annual Report and Cost Audit Report for FY26. Consequently, the trading window for designated persons has been closed since Jul 01, '26, and will reopen 48 hours after the results are declared.
The Board of Directors of the comoany at the meeting held on Wednesday, May 27, 2026 recommnded payment of Final Dividend of Rs. 1.00 per Equity Share of the face value of Rs. 10.00 each ....
Dividend · 28 May 2026, 5:51 pm
Medicamen Biotech Announces FY26 Dividend and Key Appointments On 27-May'26, Medicamen Biotech's board approved FY26 results and a final dividend of Rs 1.00 per share (face value Rs 10.00), pending shareholder approval. For FY26, consolidated net profit rose 49.4% YoY to Rs 979.64 lacs, while revenue increased 19.0% YoY to Rs 20,088.29 lacs. The board also approved the appointment of M/s SPB & Co as Cost Auditor and M/s Cheena & Associates as Internal Auditor for FY 2026-27. Statutory auditors issued an unmodified opinion on the financial results.
Statement of Deviation & Variation Report - March 31, 2026
Others (Uncategorized) · 28 May 2026, 5:43 pm
Medicamen Biotech: No Deviation in Utilization of Preferential Issue Funds Medicamen Biotech reported no deviation or variation in the use of funds for the quarter ended 31-Mar'26. The company raised Rs. 53.57 crore via a preferential issue on 24-Apr'25 for drug development, working capital, capex, and expansion. As of the reporting date, Rs. 29.30 crore has been utilized, with no change in the stated objectives for the fund usage. The Audit Committee reviewed and confirmed there was no deviation in the utilization of funds.
Audited Standalone & Consolidated Financial Results for the quarter and year ended on March 31, 2026
Financial Result · 27 May 2026, 8:56 pm
Medicamen Biotech Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 6,065 (+104.8% YoY | +29.3% QoQ) ■ EBITDA: 544 (Loss to Profit YoY | +24.3% QoQ) ■ EBITDA Margin (%): 9.0 (Loss to Profit YoY | -36 bps QoQ) ■ PAT: 386 (+59.6% YoY | +76.3% QoQ) ■ EPS (INR): 3.28 (+123.1% YoY | +171.1% QoQ)
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve the audited financial results ....
Intimation · 27 May 2026, 5:30 am
Medicamen Biotech Board Meeting on May 27 to Consider FY26 Results and Dividend Medicamen Biotech has scheduled a Board Meeting on 27 May'26 to consider and approve its audited standalone and consolidated financial results for the quarter and year ended 31 Mar'26. The board will also consider a potential recommendation for a final dividend for the financial year 2025-26. Additionally, the appointment of Cost and Internal Auditors for FY 2026-27 is on the agenda. The trading window for insiders has been closed since 01 Apr'26 and will reopen 48 hours after the results are declared.
Intimation regarding Incorrent Event Display on NSDL Portal
Others (Uncategorized) · 06 Apr 2026, 9:51 pm
Medicamen Biotech Clarifies Incorrect Event on NSDL Portal Medicamen Biotech informed exchanges on 06 Apr'26 that an event displayed on the NSDL portal under its credentials is incorrect and inadvertent. The company has clarified that it has not initiated, authorized, or undertaken any such event. Management has contacted NSDL for verification and rectification, confirming there is no material event or information requiring disclosure.
The company has on 27.01.2026 received a cautionery letter (Email) from NSE for observations reported by the Secretarial Auditor in ASCR for FY ended 31.03.2025.
Others (Uncategorized) · 21 Feb 2026, 10:17 pm
Medicamen Biotech Receives Cautionary Letter from NSE Medicamen Biotech received a cautionary letter from the NSE on 27 Jan '26 regarding observations made by its Secretarial Auditor. The observations were detailed in the Secretarial Compliance Report for the financial year ended 31 Mar '25. The NSE has advised the company to be careful to avoid future recurrence of such lapses and to adhere to listing regulations. Medicamen Biotech stated there is no impact on its financials, operations, or other activities from this communication.
Corrigendum- Intimation regarding completion of term of Independent Directorship of Mr Harish Pande and Mr Arun Kumar
Change in Management · 18 Feb 2026, 11:31 pm
Medicamen Biotech Corrects Retirement Date for Two Independent Directors Medicamen Biotech issued a corrigendum to correct the retirement date for Independent Directors Mr. Harish Pande and Mr. Arun Kumar. Due to a typographical error in its 13 Feb'26 filing, the company has clarified that the correct date of their cessation from the Board is 26 Feb'26, not 13 Feb'26. Both individuals ceased to be Independent Directors effective from the rectified date.
Pursuant to Regulation 30 of the SEBI (Listing Obligatons and Disclosure Requirements) Regulations 2025, the Company hereby informs that Mr. Harish Pande and Mr. Arun Kumar have completed ....
Change in Management · 13 Feb 2026, 9:55 pm
Medicamen Biotech Announces Independent Director Departures and Committee Changes Medicamen Biotech announced that Independent Directors Mr. Harish Pande and Mr. Arun Kumar have completed their terms effective 13-Feb'26. Consequently, they have ceased to be members and chairpersons of various board committees, including Audit, Nomination & Remuneration, and CSR. Following this, Mr. Sham Goel and Mr. Ashwani Kumar Sharma will continue as Chairpersons and Members of these key committees. The board had previously appointed Mr. Sham Goel and Mr. Shaival Saurabh as Non-Executive Independent Directors effective 12-Aug'25.
Unaudited Financial Results for the quarter ended on December 31, 2025
Financial Result · 13 Feb 2026, 9:29 pm
Medicamen Biotech Q3FY26 Consolidated PAT Declines 44.5% YoY Medicamen Biotech's consolidated net profit for Q3 ended 31 Dec'25 fell 44.5% YoY to ₹163.47 lakhs from ₹292.20 lakhs. Revenue from operations remained flat YoY at ₹4,690.85 lakhs. Sequentially, PAT decreased by 22.7% QoQ while revenue saw a slight decline of 0.6%. The company also announced the cessation of two Independent Directors, Mr. Harish Pande and Mr. Arun Kumar, effective 13 Feb'26 upon completion of their tenures, leading to the reconstitution of several board committees.
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve the unaudited consolidated ....
Intimation · 13 Feb 2026, 5:30 am
Medicamen Biotech Sets Board Meeting for Q3 FY26 Results Medicamen Biotech Limited has scheduled a Board of Directors meeting on 13 Feb'26 to consider and approve its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 Dec'25. In connection with this, the trading window for designated persons will remain closed until 15 Feb'26.
Announcement under Regulation 30 (LODR) - EU approval for product registration of Paracetamol from Danish Medicine Authority with XGX Pharma - Denmark
Others (Uncategorized) · 07 Jan 2026, 9:29 pm
Medicamen Biotech Receives EU Approval for Paracetamol Medicamen Biotech announced on 07 Jan'26 that it has received EU approval for the product registration of "Paracetamol". The approval was granted by the Danish Medicine Authority in partnership with XGX Pharma, Denmark. This development marks a significant regulatory milestone, opening access to the European market for the company's Paracetamol product.
Financial Results for the quarter and half year ended on September 30, 2025
Financial Result · 14 Nov 2025, 9:52 pm